Abbott Laboratories stock ends the day modestly higher at the close
Published on 09/21/2026 at 23:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories stock closed modestly higher on the NYSE at an official regular-session price that left the shares above their prior level, following a recent move where Abbott Laboratories stock finished at USD 101.88 on the NYSE on September 18, 2026, down 2.0 percent from the previous session. Compared with that prior close and recent three?month gains of more than 14 percent, the company’s U.S.?listed shares continued to trade within a recovering range that has lifted the stock from about USD 89.90 three months ago.
September 21, 2026 in numbers
Abbott Laboratories Inc. (ISIN US0028241000, NYSE: ABT) previously closed at USD 101.88 on the NYSE on September 18, 2026, after a session that saw a trading range between USD 101.80 and USD 104.23 and volume of 5,432,100 shares, according to a corporate?news summary from Ad-hoc-news. Over the latest three?month period, the shares have climbed about 14 percent from around USD 89.90, as shown by data provider AltIndex, placing today’s close within a strengthened medium?term uptrend. Against this backdrop, the broader market’s health?care names and wearable?sensor plays have moved more mixedly, with ABT recently indicated up about 0.19 percent in a sector snapshot from Yahoo Finance, suggesting that Abbott’s performance has been broadly in line with specialized peers.
After the bell and next trading day
After the close on September 21, 2026, legal and regulatory developments remained in focus. North Carolina’s attorney general announced that Abbott Laboratories and other parties had agreed to a USD 384 million settlement to resolve Medicaid fraud allegations tied to contaminated baby formula claims, according to WITN, which helps explain continued attention on the stock’s legal exposure. Separately, a market brief highlighted that Abbott had agreed to a USD 385 million civil settlement over alleged contaminated infant formula from its Sturgis and Casa Grande plants and confirmed a quarterly dividend of USD 0.63 per share payable on November 16, 2026, as reported by TradingView. These after?hours disclosures set the tone for the next U.S. trading day on September 22, 2026, when investors will continue to weigh Abbott’s legal settlements and dividend stream against its recent share?price recovery and the broader health?care sector’s path.
